GLP-1’s drugs continue to expand horizons in gastroenterology, bariatrics, diabetes and chronic disease care — but the scale of the drugs’ adoption could be creating new areas of risk management for physicians, according to a report published Risk & Insurance April 29.The first wave of concern relates to the proliferation of compounded medications and counterfeit products, according to the report. The FDA has raised concerns about unauthorized and improperly compounded GLP-1 formulations that may contain incorrect dosages or ingreidnets.
Keep Reading
Add A Comment